Stable anti-PD-1 antibody pharmaceutical preparation and application thereof in medicine
A stable anti-PD-1 antibody pharmaceutical preparation and an application thereof in a medicine. The anti-PD-1 antibody pharmaceutical preparation comprises an anti-PD-1 antibody, a buffer, and can further comprise at least one type of stabilizer, and optionally can further comprise a surfactant. The anti-PD-1 antibody pharmaceutical preparation of the present invention can effectively suppress antibody aggregation and deamidation, thereby preventing degradation of an antibody product, resulting in a stable injectable pharmaceutical preparation.
1. A pharmaceutical formulation, comprising an anti-PD-1 antibody, wherein the antibody comprises a heavy chain having the amino acid sequence of SEQ ID NO: 7, and a light chain having the amino acid sequence of SEQ ID: 8; and
(i) 90 mg/ml α,α-trehalose dihydrate, and 10 mM acetate buffer at pH 5.2; or
(ii) 90 mg/ml α,α-trehalose dihydrate, 0.2 mg/ml polysorbate 20, and 10 mM acetate buffer at pH 5.2; or
(iii) 90 mg/ml α,α-trehalose dihydrate, 0.2 mg/ml polysorbate 20, and 20 mM acetate buffer at pH 5.4; or
(iv) 60 mg/ml α,α-trehalose dihydrate, 0.4 mg/ml polysorbate 20, and 20 mM acetate buffer at pH 5.0; or
(v) 60 mg/ml α,α-trehalose dihydrate, 0.1 mg/ml polysorbate 20, and 20 mM acetate buffer at pH 5.2; or
(vi) 60 mg/ml α,α-trehalose dihydrate, 0.2 mg/ml polysorbate 20, and 10 mM acetate buffer at pH 5.2; or
(vii) 30 mg/ml α,α-trehalose dihydrate, 0.4 mg/ml polysorbate 20, and 10 mM acetate buffer at pH 4.8; or
(viii) 30 mg/ml α,α-trehalose dihydrate, 0.2 mg/ml polysorbate 20, and 30 mM acetate buffer at pH 5.2; or
(ix) 30 mg/ml α,α-trehalose dihydrate, 0.4 mg/ml polysorbate 20, and 10 mM acetate buffer at pH 5.6.
2. The stable anti-PD-1 antibody pharmaceutical formulation according to claim 1 , wherein the pharmaceutical formulation is an injectable pharmaceutical formulation which further comprises water for injection.
3. A lyophilized powder prepared from the pharmaceutical formulation according to claim 2 .
4. The lyophilized powder according to claim 3 , wherein an optimum drying temperature of −10° C. to −5° C. is used in lyophilization process.
5. An injection solution, obtained by dissolving the lyophilized powder according to claim 3 .
6. A stable anti-PD-1 antibody pharmaceutical formulation comprising:
(i) an anti-PD-1 antibody comprising a heavy chain having the amino acid sequence of SEQ ID NO: 7 and a light chain having the amino acid sequence of SEQ ID NO: 8;
(ii) a buffer selected from the group consisting of an acetate buffer, a citrate buffer, a succinate buffer, and a phosphate buffer;
(iii) a stabilizer selected from the group consisting of a saccharide and an amino acid, and
(iv) a surfactant selected from the group consisting of polyoxyethylene hydrogenated castor oil, a glycerol fatty acid ester, and a polyoxyethylene sorbitan fatty acid ester.
7. The pharmaceutical formulation according to claim 6 , wherein the concentration of the anti-PD-1 antibody is in the range of 1 mg/ml to 60 mg/ml.
8. The pharmaceutical formulation according to claim 7 , wherein the concentration of the anti-PD-1 antibody is 40 mg/ml.
9. The stable anti-PD-1 antibody pharmaceutical formulation according to claim 6 , wherein the pharmaceutical formulation is an injectable pharmaceutical formulation which further comprises water for injection.
10. A lyophilized powder prepared from the pharmaceutical formulation according to claim 6 .
11. The lyophilized powder according to claim 10 , wherein an optimum drying temperature of −10° C. to −5° C. is used in lyophilization process.
12. The pharmaceutical formulation according to claim 6 , wherein the buffer is the acetate buffer.
13. The pharmaceutical formulation according to claim 12 , wherein the concentration of the buffer is 1-50 mM.
14. The pharmaceutical formulation according to claim 6 , wherein the pH of the formulation ranges from 4.5 to 6.0.
15. The pharmaceutical formulation according to claim 6 , wherein the at least one stabilizer comprises a disaccharide selected from the group consisting of sucrose, lactose, trehalose, and maltose.
16. The pharmaceutical formulation according to claim 15 , wherein the disaccharide is at a concentration from 30 mg/ml to 120 mg/ml.
17. The pharmaceutical formulation according to claim 6 , wherein the surfactant is the polyoxyethylene sorbitan fatty acid ester selected from the group consisting of polysorbate 20, 40, 60 and 80.
18. The pharmaceutical formulation according to claim 17 , wherein the surfactant is at a concentration from 0.01 mg/ml to 1 mg/ml.